GetTopicDetailResponse(id=6173486930, topicName=Clovis, introduction=Clovis, content=null, image=null, comments=4, allHits=1034, url=https://h5.medsci.cn/topic?id=4869, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=41026, tagList=[TagDto(tagId=41026, tagName=Clovis)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2054905, encodeId=17c6205490553, content=<a href='/topic/show?id=6173486930' target=_blank style='color:#2F92EE;'>#Clovis#</a>, objectTitle=Clovis的Rubraca超越了多個(gè)PARP抑制劑競(jìng)爭(zhēng)對(duì)手，在前列腺癌領(lǐng)域獲得FDA的優(yōu)先審查, objectType=article, longId=186457, objectId=94c818645e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94c818645e5b, replyNumber=0, likeNumber=88, createdTime=2020-09-05, rootId=0, userName=ms705947299214030, userId=64462500151, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94c818645e5b, moduleTitle=Clovis的Rubraca超越了多個(gè)PARP抑制劑競(jìng)爭(zhēng)對(duì)手，在前列腺癌領(lǐng)域獲得FDA的優(yōu)先審查, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=94c818645e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054904, encodeId=d375205490460, content=<a href='/topic/show?id=6173486930' target=_blank style='color:#2F92EE;'>#Clovis#</a>, objectTitle=Clovis Oncology宣布?xì)W洲委員會(huì)批準(zhǔn)Rubraca用于復(fù)發(fā)性卵巢癌的維持治療, objectType=article, longId=158910, objectId=54ad1589109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ad1589109b, replyNumber=0, likeNumber=80, createdTime=2019-01-30, rootId=0, userName=ms705947299214030, userId=64462500151, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ad1589109b, moduleTitle=Clovis Oncology宣布?xì)W洲委員會(huì)批準(zhǔn)Rubraca用于復(fù)發(fā)性卵巢癌的維持治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=54ad1589109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054903, encodeId=eda32054903f4, content=<a href='/topic/show?id=6173486930' target=_blank style='color:#2F92EE;'>#Clovis#</a>, objectTitle=Clovis公司的PARP抑制劑美國(guó)獲批用于復(fù)發(fā)性卵巢癌的維持治療, objectType=article, longId=134828, objectId=ba40134828dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba40134828dd, replyNumber=0, likeNumber=83, createdTime=2018-12-23, rootId=0, userName=ms705947299214030, userId=64462500151, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba40134828dd, moduleTitle=Clovis公司的PARP抑制劑美國(guó)獲批用于復(fù)發(fā)性卵巢癌的維持治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ba40134828dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2054902, encodeId=f1da205490287, content=<a href='/topic/show?id=6173486930' target=_blank style='color:#2F92EE;'>#Clovis#</a>, objectTitle=FDA批準(zhǔn)Clovis PARP抑制劑rucaparib, objectType=article, longId=84882, objectId=d7298488274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7298488274, replyNumber=0, likeNumber=82, createdTime=2017-09-15, rootId=0, userName=ms705947299214030, userId=64462500151, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7298488274, moduleTitle=FDA批準(zhǔn)Clovis PARP抑制劑rucaparib, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d7298488274)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
